Medtronic (NYSE: MDT) reported its Q2 fiscal 2025 results (fiscal ends in April) last week, with revenues and earnings ...
Medtronic (NYSE:MDT) has plans to submit its MiniMed 780G for an expanded indication from the FDA for type 2 diabetes in the near future.
With a new smartphone app clearance from the FDA, Medtronic said it has all the pieces necessary to deliver a complete ...
Medtronic is raising its full-year guidance following second-quarter results that came in ahead of the consensus forecast.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback